Cytokines sit at the crossroads of immunology, biotechnology, and therapeutic innovation. They are signaling proteins with outsized influence: modulating immune responses, orchestrating cellular communication, and increasingly becoming the backbone of modern biologics. For Contract Development and Manufacturing Organizations (CDMOs), cytokines represent both an opportunity and a challenge. They promise lucrative markets in regenerative medicine, oncology, […]
Tag: Lipopolysaccharides
Precision Fermentation at Scale: What Biopharma Can Learn From Food Tech
Introduction: The Strange Mirror of Biopharma and Food Biopharma has long viewed itself as the high temple of fermentation. From the earliest recombinant insulin made in E. coli to monoclonal antibodies expressed in CHO cells, the industry has prided itself on scientific rigor, regulatory discipline, and painstaking optimization. Each bioreactor is treated like a cathedral of sterility […]
Beyond E. coli: Unlocking Non-Traditional Hosts in Biologics Manufacturing
Introduction: Why “Beyond E. coli” Matters For decades, E. coli has been the undisputed workhorse of microbial biomanufacturing. From recombinant insulin in the 1980s to a vast array of enzymes, antibody fragments, and research proteins, E. coli has set the standard for scalability, cost efficiency, and genetic tractability. Yet as the biologics landscape becomes increasingly complex—spanning full-length antibodies, […]
Harnessing Bacillus as a Manufacturing Platform: A CDMO Perspective
Among microbial expression hosts, Bacillus has carved out a unique niche in biomanufacturing. Unlike Gram-negative bacteria such as E. coli, Bacillus subtilis and related species are naturally endotoxin-free, simplifying downstream purification and expanding their appeal for therapeutic proteins, enzymes, and next-generation biologics. For a Contract Development and Manufacturing Organization (CDMO), mastery of Bacillus systems requires balancing its advantages—secretion capability, GRAS status, industrial […]
Overcoming Endotoxin Challenges in Therapeutic Phage Manufacturing: A CDMO Perspective
Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP […]